<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03529539</url>
  </required_header>
  <id_info>
    <org_study_id>PSV</org_study_id>
    <nct_id>NCT03529539</nct_id>
  </id_info>
  <brief_title>Expanded Access for PSV Personalized Oncolytic Viruses</brief_title>
  <acronym>PSV</acronym>
  <official_title>Expanded Access for PSV Personalized Oncolytic Viruses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EpicentRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EpicentRx, Inc.</source>
  <brief_summary>
    <textblock>
      A compassionate use, expanded access protocol for patients who have exhausted all standard&#xD;
      therapy having progressed on chemotherapy and immunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive intratumoral or subcutaneous injection of an oncolytic virus called PSV&#xD;
      (short for Personalized Virus) every other week until the occurrence of immune related RECIST&#xD;
      progression, intolerable toxicity, change to another anti-cancer treatment due to lack of&#xD;
      apparent benefit, or personal choice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PSV</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to understand and sign a written informed consent form.&#xD;
&#xD;
          -  Measurable or evaluable disease with least one (1) tumor that is accessible to&#xD;
             intratumoral injection.&#xD;
&#xD;
          -  Eastern Cooperative Group (ECOG) performance status is 0-3 at Screening.&#xD;
&#xD;
          -  Acceptable liver function at Screening, as evidenced by:&#xD;
&#xD;
               -  Bilirubin ≤ 3.0 X upper limit of normal (ULN) since this patient has&#xD;
&#xD;
               -  been diagnosed with Gilbert's Disease&#xD;
&#xD;
          -  AST (SGOT) and ALT (SGPT) ≤ 5 X ULN.&#xD;
&#xD;
          -  Serum creatinine &lt; 3 x institution upper limit of normal.&#xD;
&#xD;
          -  Patient has acceptable hematologic status at Screening, as evidenced by:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500 cells/mm3; and&#xD;
&#xD;
               -  Platelet count ≥ 70,000/mm3; and&#xD;
&#xD;
               -  Hemoglobin (HGB) ≥ 8.5 g/dL.&#xD;
&#xD;
          -  Medically acceptable contraception.&#xD;
&#xD;
          -  Willingness to comply with all protocol procedures, evaluations and rescue measures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of a serious co-morbid medical condition, or a clinically significant&#xD;
             laboratory finding(s) that, in the opinion of the Investigator, suggests the presence&#xD;
             of an infectious, endocrine, and/or other inadequately treated systemic disorder.&#xD;
&#xD;
          -  An active bacterial, fungal, or viral infection.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>John Morris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 7, 2018</study_first_submitted>
  <study_first_submitted_qc>May 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <last_update_submitted>March 4, 2019</last_update_submitted>
  <last_update_submitted_qc>March 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

